Heineken says weight-loss drugs could reduce alcohol consumption
The world's second-largest brewer advised hospitality customers that GLP-1 medications like Wegovy may lead to fewer drinks in pubs and bars.

Heineken said the use of GLP-1 medications, such as Ozempic and Wegovy, could reduce the desire to drink alcohol. This could result in fullness and fewer serves of pints in pubs and bars, the company added. The brewer noted that the GLP-1 era could make the tradition of multi-pint drinking sessions less frequent.
The Netherlands-headquartered company shared a presentation with British hospitality customers earlier this month to help them understand evolving consumer habits. Heineken advised businesses to promote half pints, low- and zero-alcohol options, and pairing drinks with small plates of food to avoid declines in customer visits and spending.
A Heineken spokesperson said the company is monitoring how these behaviours evolve in 2027. The spokesperson said GLP-1 users are not simply replacing alcohol but are becoming more purposeful in their choices and broadening their preferences. These behaviours reflect broader trends towards health, wellbeing, moderation, and intentional consumption.
Research by JP Morgan shows 10 million people in the US turned to these medications last year as consumers seek quick weight loss solutions. In the year to February, there were almost £14bn in beer sales in British pubs, bars, and restaurants, with less than £300m coming from no- and low-alcohol products.
Diageo told investors that any impact from GLP-1 drugs becoming mainstream should be manageable, while Carlsberg told Reuters that data did not support the view that weight-loss drugs affect beer consumption trends. However, surveys by research companies including Circana, NIQ, and KAM have pointed to reduced drinking by GLP-1 users.
Key facts
- Heineken advised hospitality customers to offer smaller serves and low-alcohol options due to the rise of GLP-1 drugs.
- Ten million people in the US used GLP-1 medications for weight loss last year.
- British pub and restaurant beer sales reached almost £14bn in the year to February.
Three perspectives
Neutral
Heineken is monitoring how GLP-1 medication use affects consumer behaviour and alcohol consumption.
Positive
Heineken provided advice to hospitality businesses to help them adapt to changing consumer habits.
Negative
The use of weight-loss drugs could lead to fewer drink serves and a decline in customer spending in pubs and bars.
Your week in news, every Wednesday
The biggest stories of the week for your edition, in your inbox every Wednesday morning, your time. Free, and you can unsubscribe at any time.